34.71

7.64% -2.87

Roivant Sciences Ltd (ROIV)

Overview News Price History Option Chain Financials Why ROIV Down? Discussions Forecast

Roivant Sciences Ltd stock is traded at $34.71, with a volume of 8.76M. It is down -7.64% in the last 24 hours and up +2.57% over the past month. Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Previous Close:

$37.58

Open:

$37.01

24h Volume:

8.76M

Relative Volume:

1.50

Market Cap:

$25.07B

Revenue:

$8.26M

Net Income/Loss:

$-397.91M

P/E Ratio:

-68.92

EPS:

-0.5036

Net Cash Flow:

$-758.56M

1W Performance:

-4.38%

1M Performance:

+2.57%

6M Performance:

+19.94%

1Y Performance:

+190.70%

1-Day Range:

$34.69

$37.13

1-Week Range:

$34.69

$37.81

52-Week Range:

$11.85

$37.97

Roivant Sciences Ltd Stock (ROIV) Company Profile

Name

Roivant Sciences Ltd

Sector

Healthcare (1080)

Industry

Biotechnology (605)

Phone

441-295-5950

Address

7TH FLOOR, 50 BROADWAY, LONDON

Employee

721

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

ROIV's Discussions on Twitter

Compare ROIV vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ROIV Roivant Sciences Ltd	34.71	26.61B	8.26M	-397.91M	-758.56M	-0.5036
VRTX Vertex Pharmaceuticals Inc	541.69	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	794.19	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,023.21	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	137.99	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	207.88	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-20-26	Initiated	Bernstein	Outperform
Sep-02-25	Initiated	Citigroup	Buy
Jul-10-25	Resumed	Goldman	Buy
Feb-15-24	Initiated	Wolfe Research	Outperform
Jan-05-24	Initiated	Piper Sandler	Overweight
Dec-12-23	Initiated	Deutsche Bank	Buy
Oct-17-23	Initiated	Guggenheim	Buy
Jun-08-23	Initiated	BofA Securities	Neutral
Oct-27-22	Initiated	JP Morgan	Overweight
May-23-22	Initiated	SVB Leerink	Outperform
Apr-29-22	Initiated	Cantor Fitzgerald	Overweight
Dec-15-21	Initiated	Goldman	Buy
Nov-08-21	Initiated	H.C. Wainwright	Buy
Oct-28-21	Initiated	Citigroup	Buy
Oct-26-21	Initiated	Cowen	Outperform
Oct-26-21	Initiated	Jefferies	Buy
Oct-26-21	Initiated	Truist	Buy

View All

Roivant Sciences Ltd Stock (ROIV) Latest News

Aug 21, 2026

Roivant (NASDAQ: ROIV) CIO sells option shares near $37 - Stock Titan

Aug 21, 2026

ROIV Stock Nears Record High –Retail Traders See Breakout After Surprise Earnings Beat - Stocktwits

Aug 21, 2026

107,786 Shares in Roivant Sciences Ltd. $ROIV Purchased by Great Lakes Advisors LLC - MarketBeat

Aug 21, 2026

Aug 20, 2026

Is Roivant Sciences (ROIV) Fully Valued As First Quarter Results Show A Narrower Loss? - Sahm

Aug 20, 2026

Aug 19, 2026

Roivant Sciences (ROIV) holder plans new sale after $17M June trade - Stock Titan

Aug 19, 2026

Roivant Sciences Insider Sold Shares Worth $24,160,402, According to a Recent SEC Filing - marketscreener.com

Aug 19, 2026

Roivant President, CIO Mayukh Sukhatme disposes of USD 24.12 million in common shares - Bitget

Aug 19, 2026

Aug 18, 2026

Roivant Sciences (NASDAQ:ROIV) Insider Mayukh Sukhatme Sells 243,177 Shares - MarketBeat

Aug 18, 2026

Mayukh Sukhatme Sells 284,707 Shares of Roivant Sciences (NASDAQ:ROIV) Stock - MarketBeat

Aug 18, 2026

Roivant (ROIV) CIO sells shares after exercising $3.85 options - Stock Titan

Aug 18, 2026

Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat

Aug 18, 2026

Aug 17, 2026

Roivant Sciences stock hits all-time high at 37.06 USD By Investing.com - Investing.com Australia

Aug 17, 2026

Roivant (NASDAQ: ROIV) holder eyes new sale after tens of millions sold - Stock Titan

Aug 17, 2026

Roivant Sciences (ROIV) Holds Steady at $36.2 as Shares Consolidate Between Support and ResistanceDefined Outcome ETF - vinanet.vn

Aug 17, 2026

Roivant Sciences (NASDAQ:ROIV) Sets New 1-Year HighHere's Why - MarketBeat

Aug 17, 2026

Roivant Sciences stock hits all-time high at 37.06 USD - Investing.com

Aug 17, 2026

Why Is Roivant (NASDAQ:ROIV) in NASDAQ Composite Focus Before Results? - Kalkine Media

Aug 17, 2026

Why Is Roivant (NASDAQ:ROIV) a Nasdaq Healthcare Stock to Watch? - Kalkine Media

Aug 17, 2026